By Dennis Ford, Founder & CEO, Life Science Nation (LSN)
Early-stage life science companies do not fail because the science is weak. They fail because the science never becomes investable. Across therapeutics, devices, diagnostics, and digital health, failure rates approach ninety percent. The default explanation is technical risk. The data did not hold. The biology did not translate. The product did not perform. That is not what usually happens. What happens is structural. Companies are built without a system for converting discovery into something capital can evaluate, compare, and act on. They generate data before defining the problem. They raise capital before removing uncertainty. They move forward without knowing what the next decision-maker needs to see. Capital does not fund ideas. It funds signal.
Signal is what allows an investor or partner to act with confidence. It is produced when specific forms of uncertainty are systematically removed. Without signal, even strong science remains interesting but unfundable. With it, capital moves. Over the next seven articles, we will break down how that signal is created. Not through storytelling, but through the systematic reduction of risk across a defined stack. Each layer represents a different barrier to action. Each must be addressed in sequence. Investability emerges when enough of this stack has been reduced to a level that supports a decision.
- Market
- Technical
- Regulatory
- Execution
- Economic
- Financing
- Exit
The series begins where it should: with market risk. Market risk sits at the foundation. Before anything else, a real and meaningful problem must be established. It is not enough to have a promising technology. The problem must be precise, urgent, and actionable within a real system.
The clarity of the unmet need defines the problem. Urgency determines whether action is required. Identification of the buyer clarifies who decides and who pays. The current standard of care provides context for change. Differentiation defines why the product matters. Adoption of friction determines how difficult implementation is. Path to payment ensures the product can be funded. If these elements are not clear, the company is not early. It is undefined. Most companies move past this step too quickly. They begin with the science and assume the market will follow. By the time they realize it has not, they have already consumed time, capital, and credibility. When market risk is resolved, everything else begins to align. Technical work becomes purposeful. Regulatory paths become clearer. Economic value can be measured. Capital has something to anchor to. Signal begins to form.
This is where the series starts. In the articles that follow, we will move layer by layer through the stack, showing how each dimension of risk is defined, reduced, and translated into investable signal. The objective is not to simplify science. It is to make the path from discovery to capital legible and executable. The challenge in life science is not discovery.
It is the disciplined conversion of discovery into investable signal.
Market Risk
Defining Whether a Real Problem Exists
At the foundation of the De-Risk Stack is market risk. Before a founder thinks about technical validation, regulatory pathway, or fundraising strategy, there is a more basic question: does this company solve a real problem in a form the market will recognize and respond to?
This is where many early-stage life science ventures begin to drift. A founder may have compelling science, a large disease category, and years of academic work behind the technology, yet still fail to define the problem in commercial terms. Capital does not fund scientific possibilities in the abstract; it funds opportunities where a specific problem is understood, urgent, and attached to a buyer who has a reason to act.
Market risk is therefore not a question of size alone. A very large indication can still represent a weak opportunity if the unmet need is vague, the current standard of care is acceptable, or the path to payment is unclear. By contrast, a narrowly defined indication with a highly specific unmet need can be highly investable when urgency is high, the buyer is identifiable, and the product’s advantage is obvious. What matters is not breadth, but clarity.
In practice, market risk begins with the definition of unmet need. The problem must be described precisely enough that an investor, clinician, or partner can understand exactly what is broken and for whom. Urgency follows. Some conditions create pressure for action because they are life-threatening, progressive, poorly managed, or economically burdensome. Others do not. That distinction shapes adoption, tolerance for risk, and willingness to pay.
Once need and urgency are clear, attention shifts to the buyer and the system. In life science, the user, decision maker, and payer are often different actors. If you cannot
identify who decides and who pays, you do not yet have a real market thesis. At the same time, every product enters an existing standard of care. You must understand how patients are currently treated, where those approaches fail, and why change is justified.
Differentiation, adoption friction, and path to payment complete the picture. A product must be better in a way that matters—not just marginally improved in a way that is difficult to notice. It must fit into real workflows, incentives, reimbursement structures, and budget constraints. If the system cannot absorb the product, market risk remains unresolved, no matter how attractive the science appears.
Market risk is resolved when a clearly defined and urgent problem exists, a real buyer is identified, the current approach is inadequate, and the product has a credible path to adoption and payment.
Core Elements of Market Risk
- Clarity of unmet need
- Urgency
- Identification of the buyer
- Current standard of care
- Differentiation
- Adoption friction
- Path to payment
Market risk is the first layer of the De-Risk Stack, but it is only the beginning. Resolving whether a real, urgent problem exists establishes the foundation for everything that follows. Without it, progress elsewhere does not translate into investability.
This series examines each layer of the stack in sequence, outlining how risk is systematically reduced to convert scientific innovation into something capital can evaluate and fund.
In the next installment, the focus shifts to technical risk: how companies demonstrate that their product works, and how to de-risk the underlying technology in a way that builds investor confidence.
Check back next week for Technical Risk: De-Risking the Stack.
Next Phase Newsletter 
Leave a comment